A multi-institutional team of researchers has discovered that acute lymphoblastic leukemia cells metabolically adapt to the cerebrospinal fluid-filled CNS microenvironment upon migration from the bone marrow with alterations in fatty acid synthetic pathways.
Redpin Therapeutics Inc., of New York, plans to take its newly secured $15.5 million series A financing to continue developing its ion-channel based chemogenetics platform for addressing neural circuit dysfunctions such as epilepsy, neuropathic pain and Parkinson’s disease.
In late May, Novartis AG's Avexis Inc. unit gained FDA approval for Zolgensma (onasemnogene neparvovec) to treat spinal muscular atrophy, and other companies are looking to follow suit developing drugs to treat a variety of diseases of the central nervous system (CNS).
